ZyVersa Therapeutics, Inc.
ZVSA· OTC
Filed Nov 14, 2022 · 10-Q · 45 days after period end · 0001213900-22-072377
| Metric | Q3 2022 | Q3 2021 |
|---|---|---|
| Net Income | -$679.09K | -$174.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end